Hi!
I am currently studying a novel compound in CRC treatment. We see cell death induction when we treat the cell lines (HCT116 and HT29) and we wondered if the wnt pathway could be modulated by our compound. We transduced both cell lines with the plasmid 7TGC (7xTcfeGFP//SV40-mCherry) and we expected to see a big percentage of eGFP+ cells since these cells harbor wnt activating mutations on APC (HT29) and beta-catenin (HCT116). However, we get around 1% of cells eGFP+ even though the efficiency of transduction was 20%. Does anyone know what could be happening?